Indian stocks: Visit www.stage2stocks.com →

Anavex Life Sciences Corp.

Stage 4 · Declining · week 4

As of Oct 22, 2026, Anavex Life Sciences is in Stage 4, the downtrend phase, now in week 4 (since Oct 1, 2026). It closed at $1.36, 85.5% below its 52-week high and below its 200-day average, which is falling.

Anavex Life Sciences Corp. operates as a biopharmaceutical company. More about the company

$1.36
+1.33% today
$126M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is AVXL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S4 21w
S2 16w
S4 18w
S4 19w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 17w → S1 8w → S4 21w → S1 7w → S2 6w → S3 4w → S2 16w → S3 9w → S2 3w → S3 5w → S2 11w → S3 4w → S4 18w → S1 5w → S4 19w → S1 6w → S4 3w current
Total tracked: 164 weeks across 17 stage runs.

AVXL among Biotechnology489th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…489AVXLStage 4 · wk 49−42.1%
vs 52W High
-85.5%
$1.25 lo$9.35 hi
85.5% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 4
1w13w26w
Week 4, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-57.3%
200 DMA: $3.19 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.98x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-42.1%
3M
-43.3%
6M
-58.9%
YTD
-63.0%
1Y
-85.5%
Scan Membership
Breakout Watch
Latest: 2025-05-06
11 appearances in last 60 days. First seen: 2019-04-03.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 4 · Vol 0.98x
2026-10-21S4
Wk 3 · Vol 0.97x
2026-10-20S4
Wk 3 · Vol 1.66x
2026-10-19S4
Wk 3 · Vol 1.89x
2026-10-16S4
Wk 3 · Vol 1.50x
2026-10-15S4
Wk 3 · Vol 1.83x
2026-10-14S4
Wk 2 · Vol 1.25x
2026-10-13S4
Wk 2 · Vol 1.21x
2026-10-12S4
Wk 2 · Vol 1.21x
2026-10-09S4
Wk 2 · Vol 1.31x
2026-10-08S4
Wk 2 · Vol 1.50x
2026-10-07S4
Wk 1 · Vol 1.38x
Moving averages & range
50 DMA
$2.38
200 DMA
$3.19
52W High
$9.35
52W Low
$1.25
5D Low
$1.25
Resistance levels (recent highs)
20d High
$2.38
60d High
$3.56
120d High
$3.56
250d High
$8.62
Next resistance
+75.0%
to 20d High
ROE
-12.8%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 1.1

Anavex Life Sciences: quick answers

What stage is Anavex Life Sciences in?

As of Oct 22, 2026, Anavex Life Sciences (AVXL) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Anavex Life Sciences in an uptrend?

No. Anavex Life Sciences is in a Stage 4 downtrend. It trades 57.3% below its 200-day average, which is falling.

How far is Anavex Life Sciences from its 52-week high?

Anavex Life Sciences closed at $1.36 on Oct 22, 2026, 85.5% below its 52-week high of $9.35. Its 52-week low is $1.25.

How has Anavex Life Sciences performed over the past year?

As of Oct 22, 2026, Anavex Life Sciences is down 85.5% over the past year and down 63.0% so far in 2026.

Which sector and industry is Anavex Life Sciences in?

Anavex Life Sciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.